Jubilant Pharma, Aavis launch Hydroxychloroquine Sulfate tablets in US

Published On 2020-11-07 04:30 GMT | Update On 2020-11-07 04:30 GMT

New Delhi: Jubilant Pharma Ltd. and Aavis Pharmaceuticals Inc. have recently announced the launch of Hydroxychloroquine Sulfate tablets, 200 mg, a therapeutic equivalent version of Plaquenil (hydroxychloroquine sulfate) 200 mg in the U.S. market. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd.

Hydroxychloroquine Sulfate Tablets are indicated for the treatment of Malaria, Lupus Erythematosus and Rheumatoid Arthritis.

"We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S. through our marketing partner." stated Ashok Barot, Chairman, Aavis Pharmaceuticals.

"Our team is doing their best to fulfil the current surge in demand. We'll continue our efforts to be a significant and reliable supplier of this product." stated Swapnil Shah, Managing Director, Senores Pharmaceuticals, R&D partner and an affiliate of Aavis Pharmaceuticals.

"We are excited about this launch" stated Pramod Yadav, CEO, Jubilant Pharma Limited.

"We are pleased to partner with Aavis to create access for the growing demand for this product and expand our basket of offerings in the US market."

U.S. annual market size for Hydroxychloroquine Sulfate Tablets, 200 mg was approximately US$237 million (IQVIA MAT June 2020).

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of 49 radiopharmacies in the US.

Read also: Jubilant Life Sciences launches remdesivir under brand name JUBI-R in India

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Jubilant Pharma, Aavis launch Hydroxychloroquine Sulfate tablets in US

Similar News

Delhi HC Refuses to Lift Ban on Medipol Pharma After Substandard Clarithromycin, Noscapine Supplied to Armed Forces

Biocon Opens First US Manufacturing Facility in New Jersey, Invests USD 30 Million in Expansion

USFDA Reappoints Vinay Prasad to Top Medical and Scientific Role

B Pharmacy Graduate Held for Operating Unauthorized Clinic in Hyderabad

No Generics for AbbVie's Rinvoq Until 2037, Analysts See Multi-Billion Dollar Boost

Advent to Sell Zentiva to Private Equity GTCR in USD 4.8 Billion Deal, Closing Expected in 2026

Chennai Court Acquits 2 After Alleged Nitravet Haul Found to Be Paracetamol

USFDA warns pharma cos to remove misleading ads